EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... February 25, 2026 EMA Recommends Extension of Therapeutic Indications for Selpercatinib August 25, 2022 FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma February 2, 2024 EMA Recommends Granting a Marketing Authorisation for Asciminib July 8, 2022 Load more HOT NEWS Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... Active Surveillance for Low-Risk Prostate Cancer Continues to Rise Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers Tackling under-representation of Black data scientists in cancer research
